OTC Zyrtec Could Be A Star If Ads Show Efficacy Over Claritin – UCSF’s Soller
This article was originally published in The Tan Sheet
Executive Summary
A successful Rx-to-OTC switch of Pfizer's non-sedating antihistamine Zyrtec will depend largely on the marketer's ability to communicate the drug's advantages over Claritin through consumer marketing efforts, according to Bill Soller, PhD, executive director, Center for Consumer Self Care, UCSF School of Pharmacy
You may also be interested in...
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings